Actinobac Biomed
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Stage
Unattributed VC | AliveTotal Raised
$5.1MLast Raised
$1M | 4 yrs agoAbout Actinobac Biomed
Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.
Actinobac Biomed Headquarter Location
15 Pelham Road
Kendall Park, New Jersey, 08824,
United States
732-371-2694
Expert Collections containing Actinobac Biomed
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Actinobac Biomed is included in 1 Expert Collection, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Actinobac Biomed Patents
Actinobac Biomed has filed 8 patents.
The 3 most popular patent topics include:
- Autoimmune diseases
- HIV/AIDS
- Hepatotoxins
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/6/2020 | 5/4/2021 | Hepatotoxins, Autoimmune diseases, Bacterial toxins, Immunology, HIV/AIDS | Grant |
Application Date | 3/6/2020 |
|---|---|
Grant Date | 5/4/2021 |
Title | |
Related Topics | Hepatotoxins, Autoimmune diseases, Bacterial toxins, Immunology, HIV/AIDS |
Status | Grant |
Latest Actinobac Biomed News
May 26, 2021
Treatment Uses Protein found in Oral Bacterium Scott Kachlany Newswise — A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received U.S. Food and Drug Administration (FDA) approval to treat cancer patients with a therapy based on Kachlany’s discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells. The approval clears the way for Kachlany’s company, Actinobac Biomed, to initiate a phase I clinical trial in patients who have relapsed or refractory leukemia or lymphoma. Their experimental drug, Leukothera, has additionally proven effective in treating autoimmune diseases in animals, and Actinobac is also developing its use for that purpose. Unlike many treatments for cancer, Leukothera rapidly kills cancer cells but does not compromise the immune system. “Doctors and patients often have to trade efficacy for safety. However, we hope to provide patients with a treatment option that has both a strong safety profile and robust efficacy,” said Kachlany, a professor in the dental school’s Department of Oral Biology and Actinobac’s chief scientist. Clinical trials for Leukothera will begin with 24 patients but could be expanded to include an additional cohort of 20 patients or more if the response is positive, said Kachlany, who has been working on the treatment for nearly a decade. Because patients will receive Leukothera for a short time span of once a week for four weeks, he expects to gather data quickly. If Leukothera is effective, with minimal or no negative side effects, patients can continue “compassionate care” treatment, said Kachlany. The first phase of trials, which will take approximately two years to complete, will focus primarily on safety. The trial will be conducted at three sites, including Rutgers Cancer Institute of New Jersey. In the near future, Actionobac could also begin testing Leukothera in patients with other diseases such as inflammatory bowel disease, Kachlany said. Actinobac has been funded by the NIH, the New Jersey Health Foundation, and Kairos Ventures. Request an Expert
Where is Actinobac Biomed's headquarters?
Actinobac Biomed's headquarters is located at 15 Pelham Road, Kendall Park.
What is Actinobac Biomed's latest funding round?
Actinobac Biomed's latest funding round is Unattributed VC.
How much did Actinobac Biomed raise?
Actinobac Biomed raised a total of $5.1M.
Who are the investors of Actinobac Biomed?
Investors of Actinobac Biomed include Foundation Venture Capital Group, Kairos Ventures, National Cancer Institute and National Institutes of Health.
Who are Actinobac Biomed's competitors?
Competitors of Actinobac Biomed include Evotec, Inhibikase Therapeutics, Kereos, United Biomedical, Intarcia Therapeutics, Rigel Pharmaceuticals, Sutro Biopharma, Protagonist Therapeutics, Altor BioScience, Alligator Bioscience and 48 more.
You May Also Like
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).
Verva Pharmaceuticals is an exciting, clinical-stage pharmaceutical company focused on the discovery and development of therapies to treat metabolic diseases (formerly Adipogen).
Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.
Metabolic Solutions is working with a compound in the same class of drugs as two well-known diabetes medications -- Actos and Avandia which combined for sales of more than $5 billion in 2007. The firm says a potential drug Metabolic Solutions is testing now could be safer and more effective than Actos and Avandia.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.